TABLE 2.
Efficacy of retapamulin and mupirocin ointment versus S. aureus J1225 and S. pyogenes 257 following b.i.d. or t.i.d. application for 5 or 7 days
| Compound | No. of days of treatment | Antibiotic concn (%) (frequency of application) | Mean log10 reduction ± SD compared with untreated controls (CFU/wound) in straina:
|
|
|---|---|---|---|---|
| S. aureus J1225 | S. pyogenes 257 | |||
| Retapamulin | 5 | 1 (b.i.d.) | 3.4 ± 0.7 | 4.3 ± 2.2 |
| 2 (b.i.d.) | 4.2 ± 0.5 | 6.0 ± 0.1 | ||
| 2 (t.i.d.) | 4.3 ± 0.4 | ≥6.1b | ||
| Mupirocin | 5 | 2 (t.i.d.) | 4.0 ± 0.8 | 4.7 ± 2.3 |
| Retapamulin | 7 | 1 (b.i.d.) | 3.5 ± 1.0 | 4.4 ± 2.6 |
| 2 (b.i.d.) | ≥4.4b | 5.2 ± 1.3 | ||
| 2 (t.i.d.) | ≥4.4b | ≥6.0b | ||
| Mupirocin | 7 | 2 (t.i.d.) | ≥4.4b | ≥6.0b |
a
All results were statistically significant compared to nontreated controls based on Student's t test (P ≤ 0.01).
b
Bacterial counts cleared to the limit of detection (<1.7 CFU/wound).